v3.26.1
STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
Total
May 2024 Private Placement
October 2024 Private Placement
October 2025 Private Placement
Common Stock
Common Stock
May 2024 Private Placement
Common Stock
October 2024 Private Placement
Common Stock
October 2025 Private Placement
Additional Paid-in Capital
Additional Paid-in Capital
May 2024 Private Placement
Additional Paid-in Capital
October 2024 Private Placement
Additional Paid-in Capital
October 2025 Private Placement
Subscription Receivable
Accumulated Deficit
Balance at Dec. 31, 2023 $ 35,635,609       $ 1,441       $ 61,501,801       $ (11,250) $ (25,856,383)
Beginning balance, shares at Dec. 31, 2023         14,405,325                  
Sale of common stock , net of issuance costs   $ 4,943,668 $ 9,060,713     $ 60 $ 138     $ 4,943,608 $ 9,060,575      
Sale of common stock, net of issuance costs (in shares)           603,136 1,379,314              
Exercise of stock options 1,975               1,975          
Exercise of stock options (in shares)         1,829                  
Proceeds from subscription receivable 11,250                       11,250  
Exercise of warrants 2,141,128       $ 31       2,141,097          
Exercise of warrants (in shares)         312,837                  
Stock-based compensation expense and vesting of restricted stock units 2,663,539       $ 1       2,663,538          
Stock-based compensation expense and vesting of restricted stock units (in shares)         5,000                  
Net loss (14,880,787)                         (14,880,787)
Balance at Dec. 31, 2024 39,577,095       $ 1,671       80,312,594       0 (40,737,170)
Ending balance, shares at Dec. 31, 2024         16,707,441                  
Sale of common stock , net of issuance costs       $ 20,348,653       $ 418       $ 20,348,235    
Sale of common stock, net of issuance costs (in shares)               4,181,818            
Exercise of stock options $ 38,274       $ 4       38,270          
Exercise of stock options (in shares) 35,114       35,114                  
Exercise of warrants (in shares)         83                  
Stock-based compensation expense and vesting of restricted stock units $ 4,290,315       $ 1       4,290,314          
Stock-based compensation expense and vesting of restricted stock units (in shares)         10,000                  
Net loss (21,226,107)                         (21,226,107)
Balance at Dec. 31, 2025 $ 43,028,230       $ 2,094       $ 104,989,413       $ 0 $ (61,963,277)
Ending balance, shares at Dec. 31, 2025         20,934,456